

Patient 12



Supplementary Figure. S2. Rapid symptomatic relief in patient 12 treated with GSK2118436/dabrafenib. This patient's right axillary nodal tumor was punch-biopsied at baseline (prior to B-RAFi therapy), showing concurrent *B-RAF/MEK1* mutations, and became non-palpable after eleven days of continuous GSK2118436 dosing. This tumor shrinkage was associated with increased right shoulder mobility, decreased pain and right axillary and breast swelling, despite the best overall response in this patient (Table 1) not achieving partial response by RECIST criteria.